Adi Hoess - Affimed NV CEO, Member of the Management Board
| AFMD Stock | USD 0.89 0.01 1.11% |
CEO
Dr. Adi Hoess, Ph.D., was Chief Executive Officer and Member of the Management Board of Affimed N.V. since September 2011. Dr. Hoess joined Affimed in October 2010 as Chief Commercial Officer. He has more than 20 years of professional experience with an extensive background in general management, business development, product commercialization, fund raising and MA. Prior to joining Affimed, Dr. Hoess was Chief Commercial Officer at Jerini AG and Chief Executive Officer of Jenowis AG. At Jerini AG he was responsible for BD and the market introduction of Firazyr. He also played a major role in the MA process of Jerini AG with Shire. From 2000 2002 Dr. Hoess was General Manager and Vice President of the Molecular Medicine Division at CarlZeiss in Jena. Dr. Hoess began his professional career in 1993 at MorphoSys as scientist. In 1997 he became Director of BD and in 1999, Vice President of Licensing and BD since 2011.
| Age | 63 |
| Tenure | 14 years |
| Professional Marks | Ph.D |
| Phone | 49 621 560030 |
| Web | https://www.affimed.com |
Affimed NV Management Efficiency
The company has return on total asset (ROA) of (0.4942) % which means that it has lost $0.4942 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4949) %, meaning that it created substantial loss on money invested by shareholders. Affimed NV's management efficiency ratios could be used to measure how well Affimed NV manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 8 records | CEO Age | ||
| Jeremy MBA | Day One Biopharmaceuticals | 54 | |
| Chris Martin | ADC Therapeutics SA | N/A | |
| Adrian Rawcliffe | Adaptimmune Therapeutics Plc | 53 | |
| Denise ScotsKnight | Mereo BioPharma Group | 66 | |
| Paula Ragan | X4 Pharmaceuticals | 55 | |
| Amy MBA | Terns Pharmaceuticals | 54 | |
| Christopher Martin | ADC Therapeutics SA | 62 | |
| Frank BeduAddo | PDS Biotechnology Corp | 60 | |
Management Performance
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.49 |
Affimed NV Leadership Team
Elected by the shareholders, the Affimed NV's board of directors comprises two types of representatives: Affimed NV inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Affimed. The board's role is to monitor Affimed NV's management team and ensure that shareholders' interests are well served. Affimed NV's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Affimed NV's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Uwe Reusch, Head Culture | ||
| Denise Mueller, Chief Board | ||
| RPh PharmD, Chief Officer | ||
| Arndt MD, Chief Board | ||
| Angus Smith, CFO Board | ||
| Michael Wolf, Head Administration | ||
| Andreas MD, Chief Board | ||
| Mary Sandin, Vice Communications | ||
| Wolfgang Fischer, COO, Member of the Management Board | ||
| Pr Little, Founder Consultant | ||
| Adi Hoess, CEO, Member of the Management Board | ||
| Alexander Fudukidis, Head Relations |
Affimed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Affimed NV a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.49 | ||||
| Operating Margin | (87.09) % | ||||
| Current Valuation | 1.62 M | ||||
| Shares Outstanding | 16.39 M | ||||
| Shares Owned By Insiders | 6.00 % | ||||
| Shares Owned By Institutions | 23.82 % | ||||
| Number Of Shares Shorted | 702.39 K | ||||
| Price To Earning | (2.04) X | ||||
| Price To Book | 0.79 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Affimed NV is a strong investment it is important to analyze Affimed NV's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Affimed NV's future performance. For an informed investment choice regarding Affimed Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Affimed NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Affimed Stock refer to our How to Trade Affimed Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Affimed NV. If investors know Affimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Affimed NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Affimed NV is measured differently than its book value, which is the value of Affimed that is recorded on the company's balance sheet. Investors also form their own opinion of Affimed NV's value that differs from its market value or its book value, called intrinsic value, which is Affimed NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Affimed NV's market value can be influenced by many factors that don't directly affect Affimed NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Affimed NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Affimed NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Affimed NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.